Navigation Links
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Date:5/25/2011

MOUNTAIN VIEW, Calif., May 25, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy. The study (REVIVE-RP, TA-303) met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF). The detailed results of the study will be presented on June 17, 2011 at the Cancer Survivorship and Sexual Health Symposium in Washington, DC.  

"Patients who have undergone a radical prostatectomy often have significant erectile dysfunction.  Despite advancements in surgery, it can take several months or years to normalize erections.  Radical prostatectomy patients are difficult to treat but the positive results of avanafil in these patients suggest that, if approved, avanafil could be an attractive treatment option," commented John Mulhall, M.D., Director, Male Sexual & Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center and an investigator in the study. "The trial met all the primary endpoints and detailed results of the study will be presented during the upcoming Cancer Survivorship Symposium to be held in Washington DC."

Consistent with other avanafil clinical studies, successful intercourse as measured by SEP 3 was observed as early as 15 minutes after the administration of avanafil. The most common side effects were headache, flushing and nasopharyngitis, and dropouts due to adverse events were low.  There were no serious adverse events reported in the study.

The results of the TA-303 study are not required for the avanafil New Drug Application (NDA), but the fi
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the ... the greatest health care system in the world is ... while trying to serve the public. Unfortunately, Bush has ... an enormous system that none of them can first ... series of Open Letters ( http://is.gd/wdU2CM ) provides a ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
(Date:7/21/2014)... Sunset, LA (PRWEB) July 21, 2014 ... poor sleep quality are closely correlated with depression. ... Institutes of Health: "About three quarters of ... present in about 40% of young depressed adults ... in females. The symptoms cause huge distress, have ...
(Date:7/18/2014)... , July 18, 2014 Regeneron Pharmaceuticals, Inc. ... quarter 2014 financial and operating results on Tuesday, August ... Company will host a conference call and simultaneous webcast ... Conference Call InformationTo access this call, dial (888) ... the webcast may be accessed from the ,Events and ...
Breaking Biology Technology:Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3
... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... development and commercial supply agreement with Hospira ... business unit to manufacture clinical-grade Oxycyte(R). Oxycyte ... carrier. Oxycyte will be manufactured at Hospira,s ...
... on the 1918 Spanish Influenza Strain Protected Mice and ... Bird FluROCKVILLE, Md., April 14 ... NVAX ) today reported preclinical study results ... based on the 1918 Spanish influenza strain protected against ...
... - BioMS Medical Corp. (TSX: MS), a leading developer ... that the independent Data Safety Monitoring Board (DSMB) for ... dirucotide in patients with secondary progressive MS has completed ... as per the protocol. , This was the fourth ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:7/21/2014)... Mark DeCoster, the James E. Wyche III Endowed ... will present as an invited speaker at the ... Research and Development Center in Singapore. , DeCoster, ... Louisiana Tech,s Institute for Micromanufacturing, will present a ... cell and tissue models." The presentation will ...
(Date:7/21/2014)... Medicine-led study suggests that parents of obese children often ... childhood weight gain or the importance of daily physical ... , The study is published online in the ... , "Parents have a hard time changing their child,s ... Rhee, MD, and an assistant adjunct professor in the ...
(Date:7/21/2014)... resistance, and cheating in science are among the ... and mycology experts in Montreal at the three ... July 27 to August 1, 2014. Some 2,000 ... at the 14th International Congress of Bacteriology and ... and Eukaryotic Microbiology, and the 16th International Congress ...
Breaking Biology News(10 mins):Louisiana Tech University professor presents at International Bioprinting Congress 2Parents rank their obese children as 'very healthy' 2Montreal hosts International Union of Microbiology Societies congresses 2
... -- 23andMe has launched a project funded by the ... validating 23andMe,s highly-scalable platform for pharmacogenomics research. The company ... and Reinvestment Act of 2009 for "Web-based Phenotyping for ... Human Genome Research Institute. "One of ...
... in the brain called the perirhinal cortex is critical for ... for Mind and Brain have found. The perirhinal cortex ... "declarative" or conscious memories, but the new results show that ... a graduate student at UC Davis. The results were ...
... Is red seaweed a viable future biofuel? Now that ... of yeast that can make short work of fermenting galactose, ... about biofuel crops, they think of corn, miscanthus, and switchgrass. ... choice is marine biomass," said Yong-Su Jin, a U of ...
Cached Biology News:23andMe receives NIH funding to evaluate web-based research on the genetics of drug response 2Where unconscious memories form 2Seaweed as biofuel? Metabolic engineering makes it a viable option 2
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Biology Products: